2015

• patent2015/11/05

  Treatment of Cancer Use Patent for EP4 antagonist Approved in Korea

  AskAt received a notice of allowance dated November 5, 2015 from Korea Intellectual Property Rights Information Service (KIPRS) in connection with the Application No. 10-2011-7027678, a use patent of EP4 receptor antagonist for the treatment of Cancer.
  

• business2015/09/10

  AskAt announced FDA acceptance of IND for EP4 receptor antagonist (AAT-007)

  AskAt announced today that the U.S. Food and Drug Administration (“FDA”) has accepted the company’s Investigational New Drug Application (“IND”) for its EP4 receptor antagonist (AAT-007) to treat Immuno-oncology.
  

• company2015/08/24